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Abstract
The past few years have seen rapid advancements in vector-mediated gene transfer to the nervous 
system and modest successes in human gene therapy trials. The purpose of this review is to 
describe commonly-used viral gene transfer vectors and recent advancements towards producing 
meaningful gene-based treatments for central nervous system (CNS) disorders. Gene therapy trials 
for Canavan disease, Batten disease, adrenoleukodystrophy, and Parkinson’s disease are discussed 
to illustrate the current state of clinical gene transfer to the CNS. Preclinical studies are under way 
for a number of diseases, primarily lysosomal storage disorders, using a newer generation of 
vectors and delivery strategies. Relevant studies in animal models are highlighted for 
Mucopolysaccharidosis IIB and Krabbe disease to provide a prelude for what can be expected in 
the coming years for human gene transfer trials, using recent advancements in gene transfer 
technology. In conclusion, recent improvements in CNS gene transfer technology are expected to 
significantly increase the degree of disease rescue in future CNS-directed clinical trials, exceeding 
the modest clinical successes that have been observed so far.
Introduction
Neurological disorders are among the most difficult to treat with traditional pharmacological 
approaches due to the complexity of the nervous system and the physical barriers (such as 
the blood-brain barrier, BBB) that limit the distribution of many compounds into the central 
nervous system (CNS) after peripheral administration. Vector-mediated gene transfer is an 
alternative strategy to treat CNS disorders that holds much promise, especially for 
monogenic diseases.
Although significant advancements have been made using oligonucleotides to treat a variety 
of diseases and the use of either naked DNA or nanoparticle delivery of DNA, this review 
will focus on the development of viral vectors and their use in treating neurological 
disorders. The intent of this review is to provide a basic background on the most commonly 
used viral vectors and their uses in preclinical and clinical research, so that a reader can gain 
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a concise view of where the field stands and seek additional detailed information in the cited 
references.
Gene Delivery Vectors
Viruses have the natural ability to deliver genetic material to cells, which makes them an 
excellent vector for gene delivery. Lentivirus, Herpes Simplex Virus, Adenovirus and 
Adeno-Associated virus (AAV) are some of the commonly used vectors for gene delivery to 
the CNS (Table 1).
Retroviruses are a family of single-stranded (ss) RNA viruses that use reverse transcription 
to produce DNA which is randomly inserted into the host genome as a part of their life 
cycle. These viruses code for the gag, pol, and env genes which are contained in a capsid 
surrounded by a phospholipid bilayer (Leis et al., 1988). Lentivirus is a complex retrovirus 
that can transduce both non-dividing and proliferating cells (Lewis and Emerman, 1994). 
Retroviruses can integrate their genetic material into the host genome of quiescent cells of 
the CNS and confer long-term gene expression (Escors and Breckpot, 2010; Jakobsson and 
Lundberg, 2006; Wong et al., 2006). Pseudotyping, which involves modifying the envelope 
proteins on the capsid surface, can change the tropism of these viruses and also improve 
transduction efficiency (Colin et al., 2009; Desmaris et al., 2001; Greenberg et al., 2007; 
Jakobsson et al., 2006; Rahim et al., 2009). Lentiviruses have a packaging capacity of 8 kb 
of foreign DNA once the gag and pol genes are removed. The biggest advantage of retroviral 
vectors is their ability to incorporate the target gene of interest into the host chromosome of 
dividing cells, which ensures faithful transmission of the transgene to progeny cells. This 
advantage is critical when targeting a dividing cell population, such as hematopoietic cells.
Herpes Simplex Virus I (HSV-I) is a member of the Herpesviridae family which carries a 
large, linear, double-stranded (ds) DNA genome encoding about 80 viral genes (Roizman, 
1996). The glycoproteins on the capsid facilitate entry of the virion into host cells (Shieh et 
al., 1992), and once inside the cell, the virus uncoats and circularizes its linear genome into 
an episome in the nucleus without integration (Garber et al., 1993; Strang and Stow, 2005). 
Properties of HSV-1 that make it a suitable vector in treating CNS disorders include high 
transduction efficiency, large transgene capacity (152 kb), its ability to enter a state of 
latency in neurons, and its high neural tropism via retrograde axonal transport to dorsal root 
ganglia and trigeminal ganglions (Bearer et al., 2000; Berges et al., 2007). Replication-
conditional or attenuated HSV vectors are capable of transgene expression in dividing cells 
but not in non-dividing cells (Wu et al., 1996). The application of this vector is limited due 
to its high inflammatory profile but it has been used in gene delivery to cancers such as 
glioblastoma multiforme (Andreansky et al., 1997; Lou, 2003; Markert et al., 2009; Mineta 
et al., 1995).
Another vector used in clinical applications is Adenovirus. Although it shows a high neural 
tropism (Jager and Ehrhardt, 2009), the use of this vector in the CNS is limited due to its 
high toxicity in the CNS (Lozier et al., 2002; Thomas et al., 2001). This vector is more 
commonly seen in cancer treatments and is capable of packaging 25 kb of foreign DNA 
(Kochanek et al., 1996).
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Arguably the most prominent vector for gene delivery to the brain is AAV. It is an ssDNA 
virus whose genome consists of 3 capsid genes, 4 replication genes, and a gene called AAP 
contained within 3 open reading frames, flanked by inverted terminal repeats (ITRs) that 
serve in genome replication and packaging. Recombinant AAV (rAAV) is generated by 
flanking up to ~4.7 kb of foreign DNA with the ITRs and providing the viral genes in trans, 
to package the foreign DNA (but not viral genes) within the AAV capsid (Dong et al., 1996; 
Lai et al., 2010; Wu et al., 2010). The risks associated with AAV are highly reduced due to 
its non-pathogenic nature (Atchison et al., 1965) and its dependence on co-infection with a 
helper virus such as adenovirus in order to replicate and execute a lytic infection (Goncalves, 
2005; McCarty et al., 2004). The viral capsid proteins facilitate binding of the virion to cell 
surface receptors, which can vary considerably between the >100 AAV variants that have 
been identified (Gao et al., 2005). The availability of many different capsids with differing 
tropisms provides a level of cell/organ specificity that can be modulated by the choice of 
capsid. High neural tropism of some serotypes adds to other advantages of AAV which 
include its ability to confer long-term transgene expression in non-dividing cells and its 
ability to deliver genes as an extra-chromosomal episome which highly reduces the 
possibility of insertional mutagenesis and oncogenesis (Choi et al., 2006; Duan et al., 1998).
For a detailed review of viral vectors used in gene therapy, see Gray et al., 2010b and Lentz 
et al., 2011.
Current State of Clinical Research
Two primary strategies have emerged as a means to advance gene therapy into the clinical 
arena. In vivo gene transfer focuses on using viral or chemical reagents to deliver genes 
directly to patients through a single injection. Ex vivo gene transfer relies on externally 
transducing cultured cells with a therapeutic vector and placing them back into patients 
(Suhr and Gage, 1993). This section will focus on current examples of CNS gene delivery 
trials made possible through rAAV and lentiviral vectors (Table 2). Additionally, 
shortcomings associated with each approach will be discussed to emphasize areas where 
vector improvements may lead to a more meaningful clinical outcome.
The first CNS gene therapy trial utilizing AAV began in 2001 for Canavan’s disease -- an 
inherited leukodystrophy that leads to toxic accumulation of N-acetyl-aspartate (NAA) in the 
CNS, interfering with the formation of myelin sheaths (Janson et al., 2002; Kumar et al., 
2006; Leone et al., 1999). Thirteen of the 28 patients received intraparenchymal injections of 
an AAV2 vector carrying the enzyme ASPA into six brain regions. Five and ten years post-
procedure, no long-term adverse effects were detected in treated patients, and host immune 
responses to the vector were minimal. Decreased levels of NAA accumulation in the brain 
suggested a functional copy of ASPA could be delivered to the CNS (Leone et al., 2012; 
McPhee et al., 2006). Though modest phenotypic improvements could be observed in treated 
patients such as hand-grasping and increased cognitive recognition, all patients still relied on 
assistance to walk, converse, and even acknowledge people around them (Leone et al., 
2012). A similar result was observed in the 2008 trial to treat late infantile neuronal ceroid 
lipofuscinosis (LINCL), or Batten disease. Ten patients were injected with twelve 
stereotaxic injections of CLN2/AAV2 vector into six brain regions (Worgall et al., 2008). 
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While four subjects exhibited mild humoral responses to the vector, the remaining subjects 
exhibited significantly decreased rates of decline compared to untreated control subjects 
(Worgall et al., 2008). However, like the Canavan trial, only modest phenotypic 
improvements were observed in these patients without complete reversal of disease 
pathology. In conclusion, though these studies were some of the first to demonstrate the 
safety of rAAV-mediated gene delivery for CNS disorders, the breadth of gene transfer 
achieved with direct brain injections appeared insufficient to achieve a substantial rescue.
Parkinson’s disease (PD) is a neurological disease triggered by the loss of dopaminergic 
neurons in the substantia nigra and the striatum. In the context of disease pathology, PD is a 
good candidate for gene therapy. However the involvement of several genes and 
neurotrophic factors has made PD anything but a simple therapeutic goal (Gray et al., 2010). 
Despite these setbacks, PD gene therapy has pushed its way into seven different phase I and 
phase II clinical trials, demonstrating the high enthusiasm for gene therapy (Xiao et al., 
2012). Six out of the seven trials utilized AAV2 as a vehicle for delivering neurotrophic 
factors such as GDNF or glutamic acid decarboxylase (GAD) while the seventh utilizes a 
lentiviral vector (Feng and Maguire-Zeiss, 2010). Treated patients have reported 
improvements in motor function, but the treatment efficacy has been difficult to evaluate in 
the absence of an extended phase III, placebo-controlled study.
Lastly, for disorders where loss of a secreted protein results in CNS defects, ex vivo gene 
therapy offers a way to reprogram isolated patient cells for functional protein synthesis. An 
example is a 2009 trial to treat adrenoleukodystrophy (ALD) -- a demyelinating disorder 
caused by the loss of an enzyme critical for metabolizing fatty acid chains in the CNS. 
Autologous CD34+ cells were isolated from two ALD boys, genetically reprogrammed 
using a lentiviral vector carrying the missing ABCD1 gene, and then reinjected into the 
patients. Follow-up studies showed that demyelination was halted 14–16 months following 
treatment, and 24–30 months later ALD protein expression was still retained in several cell 
types (Cartier et al., 2012; 2010).
While several clinical trials have occurred, the degree of patient improvement has been 
limited. A major limitation in all of these trials is the current vector technology and the 
ongoing challenge of how to widely, efficiently, and safely transduce cells within the CNS. 
Vector technology has made considerable advancements over what is currently used in the 
clinic, and these improvements are poised to greatly improve treatment efficacy. Some of 
these advancements are outlined below.
Advancements in Vector Technology for In Vivo Gene Transfer
An ideal vector would provide widespread distribution of the transgene, large packaging 
capacity, stable gene expression, high transduction efficiency, target cell specificity, and low 
immunological responses in order to overcome current limitations. Except for the packaging 
capacity, recent advancements have been made for AAV in each of these regards. 
Improvements in other vectors have also been made in most of these areas, but will not be 
discussed in detail. For more information on Adenovirus and HSV vectors, see Lentz et al., 
2011.
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Identification of the optimal capsid is critical to effectively target the desired cells and 
tissues. Over 100 AAV variants have been identified with varying tropisms providing a 
broad toolkit for optimized delivery to target tissue/organs (Gao et al., 2005; Wu et al., 
2006). Several variants of AAV have been used in CNS applications including AAV1, 
AAV2, AAV4, AAV5, AAV6, AAV8, and AAV9 (Gray, 2012). Although AAV2 is the most 
studied serotype in clinical applications, it performs relatively poorly compared to more 
recently characterized serotypes. Direct injection in the brain parenchyma with AAV1 and 
AAV9 provides an almost exclusive neuronal tropism, a mix of neurons and glia with AAV5, 
and mostly astrocytes with AAV4 (Burger et al., 2004; Cearley and Wolfe, 2006; Davidson 
et al., 2000). More recently, AAV9 has been shown to cross the BBB and transduce neurons 
and glia in the brain and spinal cord following intravenous injection (Duque et al., 2009; 
Foust et al., 2009; Gray et al., 2011b). Current challenges to intravenous delivery of AAV9 
include high peripheral tropism, high doses required, and limited neuronal transduction in 
non-human primate cells due to the existence of pre-existing neutralizing antibodies (NAbs) 
(Gray et al., 2011b). To circumvent these problems AAV9 can be injected into the 
cerebrospinal fluid (CSF) via the lumbar cistern or cisterna magna. Using this route of 
administration still provides widespread CNS gene transfer in non-human primates, but 
avoids anti-AAV NAbs, greatly reduces the peripheral biodistribution, and uses a 
considerably lower dose (Samaranch et al., 2012; Gray et al., in press) compared to 
intravenous injection.
Tissue/cell specificity can be further manipulated by engineering the viral capsid beyond 
what is found in nature. Strategies to modify the capsid include rational mutagenesis, 
peptide insertion, and directed evolution/DNA shuffling. By introducing rational mutations 
in the capsid, novel variants of AAV can be produced which are not only optimized for 
transduction but also increase target specificity, prevent the production of circulating 
antibodies to the vector, and/or improve intracellular trafficking. As an example, AAV9.47 is 
a variant of AAV9 that is liver-detargeted but still retains high CNS tropism (Pulicherla et 
al., 2011).
To increase the specificity of the viral vector, known ligands for target cells can be 
incorporated on the capsid. This approach has been used to modify AAV2’s ability to deliver 
genes to the CNS. Unmodified AAV2 normally has limited capability for axonal transport, 
but when peptides derived from an NMDA receptor agonist and a dynein binding motif were 
incorporated on the capsid, a 10–100 fold increase of retrograde transport delivery to the 
CNS was observed (Xu et al., 2005). Similarly, novel CNS-targeted AAV vectors have been 
created by incorporating peptides obtained through phage-display biopanning (Chen et al., 
2009). When these peptides were incorporated into an AAV2 capsid, peptides generated in 
disease models specifically targeted the CNS vasculature in those models but not in wild-
type mice, and vice versa. This demonstrates the high specificity that these approaches can 
confer upon the vectors.
As opposed to rational mutagenesis, directed evolution is a process of selecting novel capsid 
variants without a priori knowledge of physical determinants. This process was developed by 
Schaffer and Maheshri (Maheshri et al., 2006; Schaffer and Maheshri, 2004) and allows for 
the recovery of clones that are highly selective for a given characteristic, above that of the 
Kalburgi et al. Page 5













parent serotypes. Error-prone polymerase chain reaction of a single serotype, DNA shuffling 
by randomly mixing multiple serotypes, and a combination of these two methods are used to 
generate library clones with various mutations (Stemmer, 1994a; 1994b). These library 
clones are pooled together and subjected to multiple rounds of selective pressure. This 
technique was successful in the isolation of two clones for delivering therapeutic genes to 
areas of the brain that suffered damage from kainic acid seizures after intravenous injection 
(Gray et al., 2010a). These clones had the benefit of near-complete loss of tropism for liver, 
heart, and muscle conferring a more favorable biodistribution profile, leading to a higher 
degree of safety.
A major rate-limiting step in gene expression, and conversion of the genome into a stable 
episome in ssAAV, is the synthesis of the second strand for transcription following the 
uncoating of AAV in the cell (McCarty et al., 2003). Transduction efficiency has been 
increased over 100-fold with the use of self-complementary (sc) AAV (McCarty et al., 
2001). scAAV vector genomes are composed of complementary copies of the DNA insert 
linked in cis through a mutated AAV inverted terminal repeat (ITR). The main disadvantage 
of using scAAV is the reduced packaging capacity of 2.3 kb. This limitation has led to the 
development of new compact promoters and polyadenylation elements (Gray et al., 2011a).
Advancements in Ex Vivo Gene Transfer: Lentiviral Correction of Bone Marrow Stem Cells
Successful treatment options for lysosomal storage diseases include enzyme replacement 
therapy (ERT) (Desnick and Schuchman, 2002), hematopoietic cell transplantation (HCT) 
(Peters et al., 2003; Souillet et al., 2003), or a combination of the two as seen in Hurler’s 
syndrome (Cox-Brinkman et al., 2006). The main problem with ERT is the efficacy of the 
enzyme to cross the BBB which limits the access of systemically injected enzyme. 
Allogeneic HCT can be used to overcome this. Hematopoietic cells, such as activated 
lymphocytes, monocytes, and microglial precursors, are able to cross the BBB and can be 
used to deliver enzymes to the CNS (Asheuer et al., 2004; Priller et al., 2001). Following 
hematopoietic stem cell (HSC) transplantation, donor derived cells migrate to the CNS and 
differentiate to form perivascular and parenchymal microglia. These cells could mediate the 
cross-correction of the enzyme in neighboring neurons and glial cells. However, the benefit 
is limited to a small subset of lysosomal storage diseases (LSDs) and is not effective in 
patients with overt neurological or aggressive infantile forms (Rovelli, 2008). Another 
limitation of allogeneic HCT is the development of Graft-vs-Host Disease (GVHD) or Host-
vs-Graft Disease (HVGD), where the immune cells are activated and cause wide-spread 
inflammation (Hwang et al., 2007).
Transplantation of autologous HSCs modified with lentiviral vectors to express the missing 
enzyme or protein may circumvent the problems associated with allogeneic HSCT (Biffi et 
al., 2011; Cartier and Aubourg, 2008; Cartier and Aubourg, 2010; Cartier et al., 1996).
Random insertion of the transgene into the host genome, initially seen as advantage of 
lentiviral vectors due to the propagation of the transgene among dividing cells, has the risk 
of insertional mutagenesis as seen in the patients treated for X-linked SCID who developed 
leukemia as a side effect of treatment (Bokhoven et al., 2009; Hacein-Bey-Abina et al., 
2003; Pike-Overzet et al., 2007). Lentiviral vectors have been made significantly safer by 
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reducing or eliminating its integration into the host genome. Directing integration to 
heterochromatin regions minimizes the risk of gene activation (Gijsbers et al., 2010) and 
increases the safety of lentiviral vectors. Other advancements in lentiviral vectors are self-
inactivating (SIN) mutations, which knock out the promoter activity of the LTR (Miyoshi et 
al., 1998; Zufferey et al., 1998), as well as non-integrating lentiviral (NIL) vectors, which 
carry mutant integrase or mutations in their LTRs that inhibit integrase binding (Apolonia et 
al., 2007; Philippe et al., 2006; Sarkis et al., 2008). These viral genomes exist in linear and 
circular forms episomally (Cara and Reitz, 1997; Philpott and Thrasher, 2007). These new 
technologies aim to improve safety of the vectors and overcome risks of cancer. For a 
detailed review on gene transfer in HSC, see Cartier and Aubourg, 2010.
Gene Therapy for Lysosomal Storage Disorders
Lysosomal storage diseases (LSDs) are a set of inherited, metabolic disorders characterized 
by reduced or absent levels of soluble lysosomal enzyme activity. Over time, loss of enzyme 
activity results in accumulation of toxic metabolic substrates, which in 70% of LSD patients 
results in debilitating neurological symptoms (Gritti, 2011; Neufeld, 1991; Sands and 
Davidson, 2006). Genzyme Corporation currently offers recombinant enzyme replacement 
therapy (ERT) for four different LSDs -- Gaucher disease, Fabry disease, 
Mucopolysaccharidosis I, and Pompe disease. ERT requires regular infusions of enzyme, 
whereas gene therapy offers a permanent source of the missing enzyme within the body after 
a single administration.
Normally when an enzyme or protein is first translated, it is trafficked to the endoplasmic 
reticulum and the Golgi apparatus to undergo post-translational modifications. A small 
percentage of modified proteins eventually become trafficked out of the lysosome and find 
their way to the cell surface to be secreted out of the cell. This secreted enzyme can be taken 
up by neighboring cells, providing cross-correction (Sands and Davidson, 2006). Gene 
therapy can take advantage of this system by transducing a small population of cells, 
correcting them to permanently produce the functional soluble enzyme and thereafter, by 
inherent cellular trafficking, pass on the therapeutic product to neighboring cells. Data from 
in vitro cross-correction and in vivo clinical studies have demonstrated that missing LSD 
enzyme expressed at levels 1–10% of normal levels can be therapeutic (Leimig et al., 2002; 
Sands and Davidson, 2006). Therefore, cross-correction allows even sub-optimal gene 
expression to make a strong impact on LSDs. However, there are a number of LSDs where 
the mutation is not in a soluble enzyme. Mutations in non-enzymatic proteins like GM2 
activators or saposins can lead to an inability of cells to activate specific lysosomal enzymes 
(Sands and Davidson, 2006). Other LSD types are characterized by mutations in integral 
lysosomal membrane proteins or proteins that assist in the intracellular trafficking of 
lysosomal enzymes. LSDs caused by a missing soluble enzyme, that is capable of cross-
correction, represent the easiest targets for gene therapy.
Several proof-of-principle studies have validated the therapeutic potential of cross-
correction, as long as the transgene is widely distributed across the CNS. One example is 
Mucopolysaccharidosis (MPS) IIB disease -- an LSD caused by a deficiency in the alpha-N-
acetyl-glucosaminidase (NAGLU) enzyme responsible for breaking down heparan sulfate in 
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the lysosome. In 2011, Fu et al. (2011) demonstrated that a single intravenous injection of 
rAAV9-NAGLU significantly improved the behavioral phenotypes and increased survival of 
treated MPS IIIB disease mice. Histological staining of target CNS tissues showed diffuse 
global transduction and pathological correction, demonstrating that gene delivery to a small 
percentage of widely distributed cells could provide therapeutic enzyme activity levels 
across the CNS (Fu et al., 2011). In Krabbe disease, a neurodegenerative disorder 
characterized by a deficiency in galactocerebrosidase (GALC), Rafi et al. (2012) 
demonstrated the potential of utilizing multiple CNS injections to optimize delivery and 
overall cross-correction. By injecting neonate mice intracerebroventricularly, 
intracerebellarly, and intravenously with rAAVrh10-GALC, high enzyme activity was 
achieved in the brain and cerebellum, and moderate to high activity was detected in the 
spinal cord and the sciatic nerve. In addition, treated mice successfully lived up to 8 months 
and gained the ability to mate and care for new-borns, among other phenotypic corrections 
(Rafi et al., 2012).
The disease paradigm of LSDs lends itself well for gene therapy applications. Encouraging 
preclinical results from murine models of MPSIIB and Krabbe disease have demonstrated 
the capacity in which new global gene transfer approaches are proving beneficial for this 
family of diseases.
Summary
In an ideal scenario, a single administration of the vector (containing the therapeutic gene) 
would confer permanent correction of the target disease. Monogenic CNS disorders, 
especially LSDs that can benefit from cross-correction, are particularly amenable to this 
approach. Clinical trials spanning the prior decade have shown positive effects resulting 
from gene transfer, but the benefit to the patients has been relatively modest. The vector 
technology, both for in vivo and ex vivo gene transfer, has advanced rapidly in the last few 
years and new approaches have been developed to significantly improve the scope and 
efficiency of gene transfer. The effectiveness of these strategies for in vivo and ex vivo gene 
transfer is being realized in preclinical animal studies, and they are poised to rapidly 
transition into the clinical realm. Clinical successes, however modest, will continue to 
generate optimism and drive the field forward. If the preclinical successes now being 
realized translate to the clinical arena, the coming years should be quite exciting indeed.
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Table 1
Vectors Used in Gene Therapy.
Viral Vector Retroviruses, HIV Herpesvirus HSV-1 Adenovirus Adeno-Associated
Virus (AAV)
Family Retroviridae Herpesviridae Adenoviridae Parvoviridae
Disease associated with parent virus Yes Yes Yes No
Transgene capacity 8 kb 150 kb 36 kb 4.7 kb ssAAV 2.2 kb scAAV
Genome ssRNA dsDNA dsDNA ssDNA
Inserts into DNA Yes No (circular episome) No No (circular episome)
Transduction of non-dividing cells Yes No Yes Yes
Innate immunity Yes Yes Yes Limited
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Table 2
CNS Gene Delivery Trials Via rAAV and Lentiviral Vectors.
Disease Phase Vector/Gene Route Reference
Batten Disease I AAVrh10/CLN2 Intracranial Worgall et al., 2008
Canavan’s II AAV2/ASPA Intracranial Leone et al., 2012; McPhee et al., 2006
Parkinson’s I AAV2/CERE-120 Intracranial Gasmi et al., 2007; Kordower et al., 2006
I AAV2/ GAD65/67 Intracranial Kaplitt et al., 2007
II AAV2/AADC Intracranial Christine et al., 2009; Eberling et al., 2008; Muramatsu et al., 2010
Adrenoleukodystrophy I HIV-1/ABCD1 Ex vivo Cartier and Aubourg, 2008; 2010
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